Adaptive Pharmacogenomics, LLC

Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients.

J Clin Pharmacol.

Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.

J Mol Cell Cardiol. 2010 Nov;49(5):864-74

Authors: Pereira NL, Aksoy P, Moon I, Peng Y, Redfield MM, Burnett JC, Wieben ED, Yee VC, Weinshilboum RM

Membrane metallo-endopeptidase (MME), also known as neutral endopeptidase 24. 11 (EC 3. 4. 24. 11), is involved in the metabolism of natriuretic peptides that play a key role in modulating cardiac structure and function.

Antihypertensive pharmacogenetics: missed opportunity.

J Hypertens. 2010 Oct;28(10):2007-9

Authors: Padmanabhan S

PMID: 20844368 [PubMed - indexed for MEDLINE]

Older adults without dementia and with lower levels in plasma of the biomarkers beta-amyloid 42/40 (protein fragments) had an increased rate of cognitive decline over a period of 9 years, according to a study in the Jan. 19 issue of JAMA. The researchers also found that this relationship was stronger among individuals with less education and lower levels of literacy.

Preliminary research suggests that use of a type of molecular imaging procedure may have the ability to detect the presence of beta-amyloid in the brains of individuals during life, a biomarker that is identified during autopsy to confirm a diagnosis of Alzheimer's disease, according to a new study.

[Personalized medicine and individual healthcare : Medical and information technology aspects].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Aug;53(8):776-82

Authors: Niederlag W, Lemke HU, Rienhoff O

The individualization of medicine and healthcare appears to be following a general societal trend. The terms "personalized medicine" and "personal health" are used to describe this process.

A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.

PLoS One. 2010;5(6):e11210

Authors: Verde Z, Ruiz JR, Santiago C, Valle B, Bandrés F, Calvo E, Lucía A, Gómez Gallego F

The identification of CYP2C9 and VKORC1 genes has strongly stimulated the research on pharmacogenetics of coumarins in the last decade. We assessed the combined influence of CYP2C9 *2 and *3, and VKORC1 c.

Personalized medicine in psoriasis: concept and applications.

Curr Vasc Pharmacol. 2010 May 1;8(3):432-6

Authors: Al-Hoqail IA

Personalized medicine is a new treatment modality where patients are the center of interest. Thus, one drug does not fit all; rather we look for a drug which fits the individual patients' disease.

Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.

Curr Opin Organ Transplant. 2010 Oct;15(5):601-7

Authors: Quteineh L, Verstuyft C

Calcineurin inhibitors (CNI) are the mainstay immunosuppressive therapy in pediatric solid organ transplantation. These drugs have narrow therapeutic window, and continuous therapeutic drug monitoring is required to keep blood levels within the therapeutic range.

Pharmacogenomics: will the promise be fulfilled?

Nat Rev Genet. 2011 Jan;12(1):69-73

Authors: Altman RB, Kroemer HK, McCarty CA, Ratain MJ, Roden D

Tools such as genome resequencing and genome-wide association studies have recently been used to uncover a number of variants that affect drug toxicity and efficacy, as well as potential drug targets.